


Amendments to the Specification:


Please amend the specification as follows.

Please replace the **Abstract including structure (I)** with the following amended **Abstract and structure (I)**:

Abstract:

Medical devices comprising an interventional component for delivering multiple beneficial agents in which a hydration inhibitor controls release of at least one beneficial agent from the device. The hydration inhibitor is relatively less hydrophilic than the beneficial agent and preferably is a drug. Suitable beneficial agents include (I), dexamethasone, estradiol, anti-proliferative agents, anti-platelet agents, anti-inflammatory agents, anti-thrombotic agents, cytotoxic drugs, agents that inhibit cytokine or chemokine binding, cell de-differentiation inhibitors, anti-lipademic agents, matrix metalloproteinase inhibitors, cytostatic drugs, or combinations of these drugs, radiopaque markers, beta-carotene, tocopherols, tocotrienols, and antioxidants






Please replace the **paragraph** beginning at **page 10, line 25** and extending to **page 11, line 3** with the following amended paragraph:


In one aspect of the present invention are disclosed compounds represented by the structural formula:

Please replace the **paragraph** beginning at **page 11, line 18** and extending to **page 14, line 4** with the following amended paragraph:


Drugs that are suitable for use in this invention include, but are not limited to,




or a pharmaceutically acceptable salt or prodrug thereof, which includes




or a pharmaceutically acceptable salt or prodrug thereof, (hereinafter alternatively referred to as A-179578 or ABT-578), and






or a pharmaceutically acceptable salt or prodrug thereof;




or a pharmaceutically acceptable salt or prodrug thereof, (hereinafter alternatively referred to as SDZ RAD or 40-O-(2-hydroxyethyl)-rapamycin);



or a pharmaceutically acceptable salt or prodrug thereof, (hereinafter alternatively referred to as A-94507).

Please replace the **paragraph** immediately under the heading “Embodiments” and beginning at **page 15, line 27** and extending to **page 16, line 5**, with the following amended paragraph:

In one embodiment of the invention is a compound of formula



In another embodiment of the invention is a compound of formula

